跳至主要内容
临床试验/ITMCTR2022000005
ITMCTR2022000005尚未招募4 期

Research on the transformation and application of ancient classic famous recipes and comprehensive evaluation of Chinese patent medicines based on real-world research

Institute Of Basic Research In Clinical Medicine,China Academy Of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational study

入排标准

年龄范围
18 至 999(—)
性别
All

入选标准

  • 1. Age =18 years old, male and female hospitalized patients;
  • 2. Meet the diagnostic criteria of western medicine for acute ischemic stroke;
  • 3. Meet the diagnostic criteria of traditional Chinese medicine for acute ischemic stroke;
  • 4. The onset time of acute ischemic stroke is less than or equal to 14 days;
  • 5. The patient or the patient's family member and guardian signed the informed consent.

排除标准

  • 1. Silent cerebrovascular disease without symptoms and signs;
  • 2. Combining severe hypertension or diabetes and other diseases, the disease cannot be controlled after treatment;
  • 3. Patients with other diseases that affect the function of limb movement, and those with limb movement dysfunction caused by lameness, osteoarthritis, rheumatoid arthritis, gouty arthritis, etc. before treatment, which may affect the neurological function examination;
  • 4. Those who were unable to independently complete daily activities due to various diseases and physical weakness before the disease had a serious impact on the efficacy evaluation;
  • 5. Those with other comorbidities and complications that affect drug evaluation: including severe cardiac insufficiency, renal insufficiency, severe mental illness, depression after stroke, dementia, and cerebral hemorrhage after cerebral infarction;
  • 6. Contraindicated groups in the instructions for Dazhu Rhodiola injection (pregnant women; those with allergic constitution or previous allergies to multiple drugs, or those who are allergic to the components in the research drug; Patients with a history of adverse reactions containing Dazhu Rhodiola);
  • 7. Those in the control group who used other dosage forms of Rhodiola rosea (tablets, capsules, etc.) in accordance with the technical guidelines for clinical research on the treatment of stroke with new traditional Chinese medicines;
  • 8. Patients considered by other researchers to be inappropriate to participate in this study.

研究者

发起方
Institute Of Basic Research In Clinical Medicine,China Academy Of Chinese Medical Sciences

相似试验